Journey Advisory Group’s ImmunityBio IBRX Stock Holding History

Journey Advisory Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159K	Buy	18,123 +3,973	+28%	+$30.1K	0.01%	280
2026 Q1	$109K	Buy	+14,150	New	+$96.9K	0.01%	241

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Journey Advisory Group's IBRX Position: Q2 2026 in Review

Journey Advisory Group increased its ImmunityBio (IBRX) stake by 28% in Q2 2026, buying an estimated $30.1K and bringing the position to 18,123 shares worth $159K. The position accounts for 0.01% of the portfolio, ranked #280.

Journey Advisory Group first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Journey Advisory Group held 18,123 shares of ImmunityBio worth $159K as of Q2 2026.
Journey Advisory Group bought 3,973 ImmunityBio shares in Q2 2026, an estimated $30.1K.
ImmunityBio made up 0.01% of Journey Advisory Group's portfolio in Q2 2026, its #280 holding.
Journey Advisory Group first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Journey Advisory Group's 13F filing for Q2 2026, filed 4 Aug 2026.